Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
Glucagon575 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A17842 | 27543499 | Br Med Bull | Non-alcoholic fatty liver disease in 2016. | 2016 | Details |
| A18111 | 27347379 | F1000Res | A computer model simulating human glucose absorption and metabolism in health and metabolic disease states. | 2016 | Details |
| A18188 | 27301803 | Metabolism | Pharmacological management of nonalcoholic fatty liver disease. | 2016 | Details |
| A18288 | 27239734 | Lab Invest | C/EBP homologous protein modulates liraglutide-mediated attenuation of non-alcoholic steatohepatitis. | 2016 | Details |
| A18313 | 27219496 | Endocr Pract | AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY. | 2016 | Details |
| A18326 | 27208776 | Biochem Biophys Res Commun | GLP-1 analogue improves hepatic lipid accumulation by inducing autophagy via AMPK/mTOR pathway. | 2016 | Details |
| A18328 | 27207510 | Diabetes | Lipodystrophy Due to Adipose Tissue-Specific Insulin Receptor Knockout Results in Progressive NAFLD. | 2016 | Details |
| A18421 | 27146014 | Annu Rev Nutr | Hormonal and Metabolite Regulation of Hepatic Glucokinase. | 2016 | Details |
| A18440 | 27134062 | Nutr Metab Cardiovasc Dis | Insulin resistance, postprandial GLP-1 and adaptive immunity are the main predictors of NAFLD in a homogeneous population at high cardiovascular risk. | 2016 | Details |
| A18484 | 27101131 | Diabetologia | Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions. | 2016 | Details |
| A18539 | 27063274 | Clin Liver Dis | Current Pharmacologic Therapy for Nonalcoholic Fatty Liver Disease. | 2016 | Details |
| A18554 | 28702244 | Clin Diabetes Endocrinol | Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in patients with Type 2 Diabetes Mellitus. | 2016 | Details |
| A18582 | 27048250 | Diabetologia | Hepatic glucose and lipid metabolism. | 2016 | Details |
| A18600 | 27040341 | Yakugaku Zasshi | [Incretin as a Novel Treatment Strategy for NAFLD/NASH]. | 2016 | Details |
| A18614 | 27032902 | J Appl Physiol (1985) | Short-term aerobic exercise training improves gut peptide regulation in nonalcoholic fatty liver disease. | 2016 | Details |
| A18692 | 26997214 | Saudi J Gastroenterol | Treatment of nonalcoholic fatty liver disease: Where do we stand? an overview. | 2017 | Details |
| A18741 | 26976710 | Endocrinol Nutr | Effect of incretin therapies compared to pioglitazone and gliclazide in non-alcoholic fatty liver disease in diabetic patients not controlled on metformin alone: An observational, pilot study. | 2016 | Details |
| A18757 | 26968296 | J Pak Med Assoc | Endocrine and metabolic effects of Glucagon like peptide 1 receptor agonists (GLP1RA). | 2016 | Details |
| A18792 | 26937139 | World J Gastroenterol | Glucagon-like peptide-1 analogue prevents nonalcoholic steatohepatitis in non-obese mice. | 2016 | Details |
| A18829 | 26914659 | Clin Drug Investig | Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-like Peptide-1 Analogs and Dipeptidyl Peptidase-4 Inhibitors. | 2016 | Details |
| A18989 | 26830854 | Endocrinol Nutr | Baseline ALT levels as a marker of glycemic response to treatment with GLP-1 receptor agonists. | 2016 | Details |
| A19050 | 26803355 | Diabetes Res Clin Pract | Circulating adiponectin levels in type 2 diabetes mellitus patients with or without non-alcoholic fatty liver disease: Results of a small, open-label, randomized controlled intervention trial in a subgroup receiving short-term exenatide. | 2016 | Details |
| A19145 | 26728692 | J Intern Med | Diabetic and nondiabetic patients with nonalcoholic fatty liver disease have an impaired incretin effect and fasting hyperglucagonaemia. | 2016 | Details |
| A19191 | 28329615 | Dermatol Online J | Necrolytic migratory erythema associated with fatty liver disease and the psuedoglucagonoma syndrome. | 2016 | Details |
| A19272 | 26663034 | Acta Physiol (Oxf) | Gastric bypass surgery is protective from high-fat diet-induced non-alcoholic fatty liver disease and hepatic endoplasmic reticulum stress. | 2015 | Details |
| A19332 | 26626496 | J Hepatol | Effects of glucagon-like peptide-1 on glucagon secretion in patients with non-alcoholic fatty liver disease. | 2015 | Details |
| A19360 | 26608256 | Lancet | Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. | 2015 | Details |
| A19469 | 26547273 | Med Hypotheses | Involvement of steatosis-induced glucagon resistance in hyperglucagonaemia. | 2015 | Details |
| A19727 | 26394161 | J Hepatol | Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis. | 2015 | Details |
| A19739 | 26381272 | Diabetes Metab Res Rev | Comparative efficacy of anti-diabetic agents on nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized and non-randomized studies. | 2015 | Details |
| A20017 | 26203166 | J Endocrinol | Hepatic insulin resistance and increased hepatic glucose production in mice lacking Fgf21. | 2015 | Details |
| A20038 | 26195184 | Expert Opin Biol Ther | Liraglutide improves carotid intima-media thickness in patients with type 2 diabetes and non-alcoholic fatty liver disease: an 8-month prospective pilot study. | 2015 | Details |
| A20113 | 26147696 | Hepatol Res | Glucagon-like peptide-1 preserves non-alcoholic fatty liver disease through inhibition of the endoplasmic reticulum stress-associated pathway. | 2015 | Details |
| A20174 | 26111358 | J Gastroenterol Hepatol | Incretin-based therapies for the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis. | 2016 | Details |
| A20234 | 26072069 | J Huazhong Univ Sci Technolog Med Sci | Review on the effect of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors for the treatment of non-alcoholic fatty liver disease. | 2015 | Details |
| A20243 | 26066519 | Toxicology | A Northern contaminant mixture impairs pancreas function in obese and lean JCR rats and inhibits insulin secretion in MIN6 cells. | 2015 | Details |
| A20272 | 26052375 | World J Hepatol | Pathophysiological mechanisms involved in non-alcoholic steatohepatitis and novel potential therapeutic targets. | 2015 | Details |
| A20373 | 26005676 | Hepatobiliary Surg Nutr | Fatty liver disease in diabetes mellitus. | 2015 | Details |
| A20393 | 25994073 | Diabetologia | Incretin-based therapies: where will we be 50 years from now? | 2015 | Details |
| A20460 | 25947915 | Biol Pharm Bull | The Glucagon-Like Peptide-1 Analogue Liraglutide Inhibits Oxidative Stress and Inflammatory Response in the Liver of Rats with Diet-Induced Non-alcoholic Fatty Liver Disease. | 2015 | Details |
| A20523 | 25910576 | Acta Biochim Biophys Sin (Shanghai) | Exendin-4 regulates redox homeostasis in rats fed with high-fat diet. | 2015 | Details |
| A20675 | 25809828 | Int J Obes (Lond) | Urinary (1)H-NMR-based metabolic profiling of children with NAFLD undergoing VSL#3 treatment. | 2015 | Details |
| A20978 | 25606030 | Case Rep Gastroenterol | A 25-year-old woman with type 2 diabetes and liver disease. | 2014 | Details |
| A21027 | 25566193 | Front Endocrinol (Lausanne) | O-GlcNAc: A Bittersweet Switch in Liver. | 2014 | Details |
| A21117 | 25531383 | Zhonghua Gan Zang Bing Za Zhi | [Liraglutide protects against nonalcoholic fatty liver disease in ApoE knockout mice with high-fat diet and silenced Acrp30 by increasing AMPK]. | 2014 | Details |
| A21126 | 25526792 | BMJ Open | Effects of lixisenatide on elevated liver transaminases: systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetes. | 2014 | Details |
| A21179 | 25496866 | Zhonghua Gan Zang Bing Za Zhi | [Influence of GLP-1 on oxidative stress injury in non-alcoholic fatty liver disease rats]. | 2014 | Details |
| A21294 | 25428903 | Am J Physiol Gastrointest Liver Physiol | Mosapride citrate improves nonalcoholic steatohepatitis with increased fecal lactic acid bacteria and plasma glucagon-like peptide-1 level in a rodent model. | 2014 | Details |
| A21315 | 25412688 | Curr Vasc Pharmacol | Incretin-Based Antidiabetic Agents for the Management of Non-Alcoholic Fatty Liver Disease. | 2015 | Details |
| A21385 | 25356042 | World J Gastroenterol | Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammation. | 2014 | Details |
| A21519 | 25258410 | Am J Physiol Gastrointest Liver Physiol | Mitigation of autophagy ameliorates hepatocellular damage following ischemia-reperfusion injury in murine steatotic liver. | 2014 | Details |
| A21723 | 25091053 | Clin Pharmacokinet | Pharmacokinetics in patients with chronic liver disease and hepatic safety of incretin-based therapies for the management of type 2 diabetes mellitus. | 2014 | Details |
| A21734 | 25083081 | World J Gastroenterol | Potential roles of glucagon-like peptide-1-based therapies in treating non-alcoholic fatty liver disease. | 2014 | Details |
| A21759 | 25066109 | Diabetes Metab Res Rev | GLP-1 receptor agonists: effects on the progression of non-alcoholic fatty liver disease. | 2014 | Details |
| A21767 | 25060692 | Metabolism | Shifts in dietary carbohydrate-lipid exposure regulate expression of the non-alcoholic fatty liver disease-associated gene PNPLA3/adiponutrin in mouse liver and HepG2 human liver cells. | 2014 | Details |
| A21861 | 24993337 | Int J Mol Med | Exendin‑4, a glucagon‑like peptide‑1 receptor agonist, modulates hepatic fatty acid composition and Δ‑5‑desaturase index in a murine model of non‑alcoholic steatohepatitis. | 2014 | Details |
| A21914 | 24966606 | World J Gastroenterol | Incretin based therapies: a novel treatment approach for non-alcoholic fatty liver disease. | 2014 | Details |
| A21945 | 24947350 | Diabetes | SIRT1 mediates the effect of GLP-1 receptor agonist exenatide on ameliorating hepatic steatosis. | 2014 | Details |
| A22106 | 24816727 | J Physiol Biochem | Bile acid supplementation improves established liver steatosis in obese mice independently of glucagon-like peptide-1 secretion. | 2014 | Details |
| A22122 | 24799988 | World J Hepatol | Insulin sensitizers for the treatment of non-alcoholic fatty liver disease. | 2014 | Details |
| A22132 | 24796231 | Hepatol Res | Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN-J). | 2014 | Details |
| A22228 | 24738701 | Aliment Pharmacol Ther | Randomised clinical trial: The beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis. | 2014 | Details |
| A22282 | 24692138 | Compr Physiol | Energy metabolism in the liver. | 2014 | Details |
| A22315 | 24669954 | Expert Opin Drug Metab Toxicol | Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease. | 2014 | Details |
| A22379 | 24630174 | Cell Calcium | Calcium-dependent regulation of glucose homeostasis in the liver. | 2014 | Details |
| A22385 | 24627601 | World J Gastroenterol | Exenatide improves hepatic steatosis by enhancing lipid use in adipose tissue in nondiabetic rats. | 2014 | Details |
| A22526 | 24490861 | Br J Pharmacol | Exendin-4 decreases liver inflammation and atherosclerosis development simultaneously by reducing macrophage infiltration. | 2014 | Details |
| A22528 | 24489924 | PLoS One | Glucose-induced glucagon-like Peptide 1 secretion is deficient in patients with non-alcoholic fatty liver disease. | 2014 | Details |
| A22672 | 24373179 | Diabetes Obes Metab | APOE*3Leiden.CETP transgenic mice as model for pharmaceutical treatment of the metabolic syndrome. | 2014 | Details |
| A22743 | 24337650 | Semin Immunopathol | Microbiota and nonalcoholic steatohepatitis. | 2013 | Details |
| A22765 | 24322742 | Hepatobiliary Pancreat Dis Int | Novel anti-diabetic agents in non-alcoholic fatty liver disease: a mini-review. | 2013 | Details |
| A22860 | 24273273 | Nan Fang Yi Ke Da Xue Xue Bao | [Effects of glucagon-like peptide-1 on liver oxidative stress, TNF-α and TGF-β1 in rats with non-alcoholic fatty liver disease]. | 2013 | Details |
| A22882 | 24256515 | Clin Endocrinol (Oxf) | Glucagon-like peptide-1 analogue, liraglutide, improves liver fibrosis markers in obese women with polycystic ovary syndrome and nonalcoholic fatty liver disease. | 2013 | Details |
| A22906 | 24222092 | Semin Liver Dis | The role of gastrointestinal hormones in hepatic lipid metabolism. | 2013 | Details |
| A23093 | 24045866 | Am J Physiol Endocrinol Metab | The rate of production of uric acid by hepatocytes is a sensitive index of compromised cell ATP homeostasis. | 2013 | Details |
| A23101 | 24040873 | Curr Pharm Des | The role of oral antidiabetic agents and incretin mimetics in type 2 diabetic patients with non-alcoholic fatty liver disease. | 2014 | Details |
| A23162 | 23994650 | Transl Res | The serum level of soluble CD26/dipeptidyl peptidase 4 increases in response to acute hyperglycemia after an oral glucose load in healthy subjects: association with high-molecular weight adiponectin and hepatic enzymes. | 2013 | Details |
| A23233 | 23935128 | Eur J Endocrinol | Elevated hepatic chemerin mRNA expression in human non-alcoholic fatty liver disease. | 2013 | Details |
| A23273 | 23909258 | Vnitr Lek | [Effects of GLP-1 (glucagon-like peptide 1) on liver]. | 2013 | Details |
| A23348 | 23851679 | Food Funct | Oat β-glucan inhibits lipopolysaccharide-induced nonalcoholic steatohepatitis in mice. | 2013 | Details |
| A23559 | 23676586 | Intern Med | Effects of liraglutide, a human glucagon-like peptide-1 analogue, on body weight, body fat area and body fat-related markers in patients with type 2 diabetes mellitus. | 2013 | Details |
| A23630 | 23613622 | World J Gastroenterol | Dipeptidyl peptidase-4: a key player in chronic liver disease. | 2013 | Details |
| A23772 | 24843641 | J Diabetes Investig | Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas. | 2013 | Details |
| A23842 | 23432843 | Liver Int | GLP-1 analogue prevents NAFLD in ApoE KO mice with diet and Acrp30 knockdown by inhibiting c-JNK. | 2013 | Details |
| A23956 | 23352496 | J Diabetes Complications | Potential of incretin-based therapies for non-alcoholic fatty liver disease. | 2013 | Details |
| A24090 | 23236362 | PLoS One | Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists. | 2012 | Details |
| A24127 | 23203768 | Mol Nutr Food Res | Prebiotic approach alleviates hepatic steatosis: implication of fatty acid oxidative and cholesterol synthesis pathways. | 2012 | Details |
| A24145 | 23182413 | Epilepsy Res | The novel insulin resistance parameters RBP4 and GLP-1 in patients treated with valproic acid: just a sidestep? | 2012 | Details |
| A24163 | 23163663 | Aliment Pharmacol Ther | Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program. | 2012 | Details |
| A24218 | 23110104 | PLoS One | E4orf1 improves lipid and glucose metabolism in hepatocytes: a template to improve steatosis & hyperglycemia. | 2012 | Details |
| A24275 | 23057494 | Aliment Pharmacol Ther | Review article: the emerging interplay among the gastrointestinal tract, bile acids and incretins in the pathogenesis of diabetes and non-alcoholic fatty liver disease. | 2012 | Details |
| A24386 | 22950055 | Diabetes Metab J | GLP-1 Receptor Agonist and Non-Alcoholic Fatty Liver Disease. | 2012 | Details |
| A24411 | 22927782 | ScientificWorldJournal | The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone. | 2012 | Details |
| A24419 | 22918684 | Dig Dis Sci | Dipeptidyl peptidase 4-deficient rats have improved bile secretory function in high fat diet-induced steatosis. | 2012 | Details |
| A24655 | 25755424 | J Clin Exp Hepatol | Management of Non-alcoholic Fatty Liver Disease and Steatohepatitis. | 2012 | Details |
| A24818 | 22467277 | Hepatology | Hepatic progenitor cells activation, fibrosis, and adipokines production in pediatric nonalcoholic fatty liver disease. | 2012 | Details |
| A24867 | 22418890 | Semin Liver Dis | The impact of bariatric surgery on nonalcoholic steatohepatitis. | 2012 | Details |
| A24966 | 22300605 | Endocrinol Nutr | The role of gut hormones in controlling the food intake: what is their role in emerging diseases? | 2012 | Details |
| A24996 | 22268099 | Am J Physiol Gastrointest Liver Physiol | Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice. | 2012 | Details |
| A25093 | 22179204 | Mol Med Rep | Increased hepatic expression of dipeptidyl peptidase-4 in non-alcoholic fatty liver disease and its association with insulin resistance and glucose metabolism. | 2011 | Details |